Wall Street analysts expect Clorox Co (NYSE:CLX) to report earnings per share (EPS) of $2.39 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Clorox’s earnings, with estimates ranging from $2.12 to $2.59. Clorox posted earnings per share of $1.59 in the same quarter last year, which would indicate a positive year over year growth rate of 50.3%. The company is scheduled to report its next earnings results on Thursday, October 29th.
On average, analysts expect that Clorox will report full-year earnings of $7.76 per share for the current year, with EPS estimates ranging from $7.40 to $7.97. For the next financial year, analysts forecast that the firm will report earnings of $8.09 per share, with EPS estimates ranging from $7.60 to $8.89. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Clorox.
Clorox (NYSE:CLX) last posted its quarterly earnings results on Monday, August 3rd. The company reported $2.41 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.41. Clorox had a return on equity of 138.70% and a net margin of 13.97%. The firm had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.86 billion. During the same period last year, the company earned $1.88 earnings per share. The business’s revenue for the quarter was up 21.9% on a year-over-year basis.
A number of analysts have recently commented on the company. Credit Suisse Group boosted their price target on Clorox from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Zacks Investment Research cut Clorox from a “buy” rating to a “hold” rating and set a $249.00 price target on the stock. in a research report on Thursday, August 6th. DA Davidson boosted their price target on Clorox from $256.00 to $269.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Citigroup boosted their price target on Clorox from $206.00 to $246.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. boosted their price target on Clorox from $203.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $202.93.
There’s an all-new way to trade before the bell rings – achieve up to 1,139% return. You could achieve 92.3% accuracy with only two key numbers.
NYSE CLX opened at $212.52 on Friday. Clorox has a twelve month low of $144.12 and a twelve month high of $239.87. The company has a market capitalization of $27.35 billion, a price-to-earnings ratio of 28.91, a PEG ratio of 3.98 and a beta of 0.23. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 3.06. The stock’s 50-day simple moving average is $227.47 and its two-hundred day simple moving average is $201.93.
In other Clorox news, SVP Denise Garner sold 25,832 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $197.62, for a total transaction of $5,104,919.84. Following the completion of the sale, the senior vice president now directly owns 17,468 shares in the company, valued at approximately $3,452,026.16. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Diego J. Barral sold 10,041 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $235.59, for a total transaction of $2,365,559.19. Following the sale, the senior vice president now owns 13,931 shares of the company’s stock, valued at $3,282,004.29. The disclosure for this sale can be found here. Insiders sold a total of 48,805 shares of company stock worth $10,522,043 over the last ninety days. 1.14% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in CLX. Geode Capital Management LLC increased its holdings in Clorox by 5.5% during the first quarter. Geode Capital Management LLC now owns 2,415,807 shares of the company’s stock valued at $417,876,000 after buying an additional 125,821 shares during the period. AQR Capital Management LLC increased its holdings in Clorox by 19.9% during the second quarter. AQR Capital Management LLC now owns 1,567,610 shares of the company’s stock valued at $343,150,000 after buying an additional 259,999 shares during the period. Bank of New York Mellon Corp increased its holdings in Clorox by 0.3% during the second quarter. Bank of New York Mellon Corp now owns 1,505,670 shares of the company’s stock valued at $330,299,000 after buying an additional 3,959 shares during the period. APG Asset Management N.V. increased its holdings in Clorox by 8,909.5% during the first quarter. APG Asset Management N.V. now owns 1,108,615 shares of the company’s stock valued at $158,426,000 after buying an additional 1,096,310 shares during the period. Finally, Legal & General Group Plc increased its holdings in Clorox by 4.2% during the first quarter. Legal & General Group Plc now owns 1,082,973 shares of the company’s stock valued at $187,522,000 after buying an additional 43,604 shares during the period. Institutional investors and hedge funds own 79.18% of the company’s stock.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Read More: Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
The quaint correction that was labeled the “tech wreck” of 2018 seems like a distant memory to investors. What also seems like a distant memory is any thought of the Federal Reserve raising interest rates.
At the end of 2018, the Federal Reserve had raised its benchmark federal funds rate. With the trade dispute with China dragging on, there was increasing pressure on the Fed to lower interest rates. When interest rates are lower, stocks will generally rise as investors have no other option for growth.
In July 2019, the doves got their wish. But in a move that now seems to be a “what did they know move”, the Fed dropped rates again in October. The market soared to record highs in January and early February. Since mid-February however, the market has fallen dramatically, and the Fed juiced the market one more time by cutting rates down to levels not seen since the financial crisis.
None of us know for sure when the U.S. economy will be opened up. And while stocks are still a good investment, not every stock is a smart investment at this time. But some stocks perform well when interest rates are falling and that’s why we’ve prepared this presentation.
These six stocks stand to benefit from both low-interest rates and the unique economic conditions being brought on by the Covid-19 pandemic.